AUROPHARMA

Aurobindo Pharma Share PriceAurobindo Pharma

₹1,021.5
  • Advice
  • Hold
As on 30 November, 2023 | 09:12 BSE: 524804 NSE: AUROPHARMAISIN: INE406A01037

Aurobindo Pharma Performance

Day Range

  • Low 0.00
  • High 0.00
₹ 1,021.5

52 Week Range

  • Low 0.00
  • High 1,058.00
₹ 1,021.5
  • Open Price1,021.50
  • Previous Close1,021.45
  • Volume1848

Start SIP in Aurobindo Pharma

Start SIP

Aurobindo Pharma Share Price

  • Over 1 Month 19.54%
  • Over 3 Month 23.24%
  • Over 6 Month 67.09%
  • Over 1 Year 118.91%

Aurobindo Pharma Key Statistics

P/E Ratio 25.7
PEG Ratio 2.5
Market Cap Cr 59,854
Price to Book Ratio 2.2
EPS 20.8
Dividend 0.6
Relative Strength Index 65.52
Money Flow Index 78.21
MACD Signal 33.74
Average True Range 26.28

Aurobindo Pharma Investment Rating

  • Master Rating:
  • Aurobindo Pharma has an operating revenue of Rs. 26,950.03 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 11% is healthy, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 41% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 9% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 69 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Aurobindo Pharma Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 2,6482,3643,4843,4182,9702,7352,878
Operating Expenses Qtr Cr 2,1241,9682,8562,9592,7302,5452,380
Operating Profit Qtr Cr 545422692473296242507
Depreciation Qtr Cr 6660115109109103101
Interest Qtr Cr 373249391985
Tax Qtr Cr 130901711065948-63
Net Profit Qtr Cr 416336645299165122802
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 13,22611,958
Operating Expenses Annual Cr 11,0619,814
Operating Profit Annual in Cr 1,7311,473
Depreciation Cr 435415
Interest Annual Cr 11517
Tax Annual Cr 384183
Net Profit Annual Cr 1,2301,455
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 1,8213,727
Cash from Investing Activity Annual Cr -3,460-1,614
Cash from Financing Annual Activity Cr 1,719-2,448
Net Cash Flow Annual Cr 81-334
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 17,91417,117
Fixed Assets Annual Cr 3,9273,811
Total Non Current Assets Annual Cr 15,21011,766
Total Current Assets Annual Cr 9,7249,835
Total Assets Annual Cr 24,93421,601
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 306292
ROE Annual % 78
ROCE Annual % 910
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1719
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 7,1516,7916,3796,3885,6746,1775,795
Operating Expenses Qtr Cr 5,8465,6995,4715,4534,9495,2994,835
Operating Profit Qtr Cr 1,3731,1511,002954791936974
Depreciation Qtr Cr 418327346321298280254
Interest Qtr Cr 6857564525159
Tax Qtr Cr 32424222418911315917
Net Profit Qtr Cr 757571506491409521576
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 25,14623,776
Operating Expenses Annual Cr 21,13719,069
Operating Profit Annual in Cr 3,7194,387
Depreciation Cr 1,2451,127
Interest Annual Cr 14049
Tax Annual Cr 685726
Net Profit Annual Cr 1,9282,648
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 2,3875,016
Cash from Investing Activity Annual Cr -3,978-3,212
Cash from Financing Annual Activity Cr 1,814-2,969
Net Cash Flow Annual Cr 223-1,164
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 26,84024,576
Fixed Assets Annual Cr 15,81813,804
Total Non Current Assets Annual Cr 18,34415,799
Total Current Assets Annual Cr 21,54618,123
Total Assets Annual Cr 39,89033,922
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 458419
ROE Annual % 711
ROCE Annual % 1014
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1620

Aurobindo Pharma Technicals

EMA & SMA

Current Price
₹1,021.5
0.05 (0%)
pointer
  • Bullish Moving Average
  • ___
  • 14
  • Bearish Moving Average
  • ___
  • 2
  • 20 Day
  • ₹978.41
  • 50 Day
  • ₹926.19
  • 100 Day
  • ₹862.57
  • 200 Day
  • ₹770.18
  • 20 Day
  • ₹965.14
  • 50 Day
  • ₹917.36
  • 100 Day
  • ₹869.71
  • 200 Day
  • ₹720.60

Aurobindo Pharma Resistance and Support

PIVOT
₹1,021.12
Resistance
First Resistance 1,032.23
Second Resistance 1,043.02
Third Resistance 1,054.13
RSI 65.52
MFI 78.21
MACD Single Line 33.74
MACD 37.74
Support
First Resistance 1,010.33
Second Resistance 999.22
Third Resistance 988.43

Aurobindo Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 2,448,245 128,998,029 52.69
Week 2,033,576 100,641,651 49.49
1 Month 2,457,904 96,472,730 39.25
6 Month 2,123,843 85,633,366 40.32

Aurobindo Pharma Result Highlights

Aurobindo Pharma Synopsis

NSE-Medical-Generic Drugs

Aurobindo Pharma is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 12792.28 Cr. and Equity Capital is Rs. 58.59 Cr. for the Year ended 31/03/2023. Aurobindo Pharma Ltd. is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190.
Market Cap 59,851
Sales 12,039
Shares in Float 28.12
No of funds 708
Yield 0.59
Book Value 3.34
U/D Vol ratio 1.3
LTDebt / Equity
Alpha 0.31
Beta 0.53

Aurobindo Pharma

Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 51.83%51.83%51.83%51.83%
Mutual Funds 11.27%8.37%7.64%7.5%
Insurance Companies 6.67%7.03%7.2%7.15%
Foreign Portfolio Investors 22.45%24.12%23.03%22.31%
Financial Institutions/ Banks
Individual Investors 6.16%7.02%8.54%9.42%
Others 1.62%1.63%1.76%1.79%

Aurobindo Pharma Management

Name Designation
Mr. K Ragunathan Non Executive Chairman
Mr. K Nithyananda Reddy Vice Chairman & Mng.Director
Mr. P Sarath Chandra Reddy Whole Time Director
Dr. M Sivakumaran Whole Time Director
Mr. M Madan Mohan Reddy Whole Time Director
Mr. P V Ramprasad Reddy Non Executive Director
Mrs. Savita Mahajan Ind. Non-Executive Director
Mr. Girish P Vanvari Ind. Non-Executive Director
Dr.(Mrs.) Avnit Bimal Singh Ind. Non-Executive Director

Aurobindo Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Aurobindo Pharma Corporate Action

Date Purpose Remarks
2023-11-09 Quarterly Results & Interim Dividend
2023-08-12 Quarterly Results
2023-05-27 Audited Results
2023-02-09 Quarterly Results & Interim Dividend
2022-11-12 Quarterly Results
Date Purpose Remarks
2023-11-20 INTERIM Rs.3.00 per share(300%)First Interim Dividend
2023-02-17 INTERIM Rs.3.00 per share(300%)Interim Dividend
2022-06-07 INTERIM Rs.4.50 per share (450%) Fourth Interim Dividend
2022-02-21 INTERIM Rs.1.50 per share(150%)Third Interim Dividend
2021-11-18 INTERIM Rs.1.50 per share (150%) Second Interim Dividend

Aurobindo Pharma MF Shareholding

Name Amount(cr)
HDFC Balanced Advantage Fund Growth 63,981
HDFC Mid-Cap Opportunities Fund Growth 47,846
ICICI Prudential Value Discovery Fund Growth 32,494
Kotak Equity Arbitrage Fund Growth 28,958
Mirae Asset Emerging Bluechip Fund Growth 28,104

Aurobindo Pharma FAQs

What is Share Price of Aurobindo Pharma ?

Aurobindo Pharma share price is ₹1,021 As on 30 November, 2023 | 08:58

What is the Market Cap of Aurobindo Pharma ?

The Market Cap of Aurobindo Pharma is ₹59853.6 Cr As on 30 November, 2023 | 08:58

What is the P/E ratio of Aurobindo Pharma ?

The P/E ratio of Aurobindo Pharma is 25.7 As on 30 November, 2023 | 08:58

What is the PB ratio of Aurobindo Pharma ?

The PB ratio of Aurobindo Pharma is 2.2 As on 30 November, 2023 | 08:58

Is it a good time to invest in Aurobindo Pharma?

Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.

How many times have Aurobindo Pharma given dividends since 2000?

Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.

What is the stock price CAGR of Aurobindo Pharma?

The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.

What is the ROE of Aurobindo Pharma?

Aurobindo Pharma has an ROE of 24% which is exceptional.

What is Aurobindo Pharma’s debt to equity?

Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.

Q2FY23